Candidiasis of skin and nail
Methodology & AI Transparency ⓘ
Candidiasis of skin and nail Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Physicians managing Candidiasis of skin and nail (B37.2; Bacterial, Viral & Fungal Infections) utilize sepsis/severity red-flag triage [Candidiasis of skin and nail B37.2] and objective Complete Blood Count in Candidiasis of skin and nail (B37.2: (WBC & Differential)) targets (WBC 4.0 – 10.0 x10^3/uL (B37.2)) to prevent progression and functional morbidity.
- 2 Real-world patient consensus: Mapped to Bacterial, Viral & Fungal Infections under ICD-10-CM B37.2 for Candidiasis of skin and nail clinical workups.
- 3 Typical cash cost range: Clinicians assessing Candidiasis of skin and nail focus on cytokine pyrogen release [Candidiasis of skin and nail B37.2] and targeted history.
- 4 Top reported side effects / signs: Objective lab/clinical target for Candidiasis of skin and nail: Complete Blood Count in Candidiasis of skin and nail (B37.2: (WBC & Differential)) (WBC 4.0 – 10.0 x10^3/uL (B37.2)) and C-Reactive Protein / in Candidiasis of skin and nail (B37.2: Procalcitonin).
Ask our AI Specialists anything about Candidiasis of skin and nail
What Is Candidiasis of skin and nail?
Physicians managing Candidiasis of skin and nail (B37.2; Bacterial, Viral & Fungal Infections) utilize sepsis/severity red-flag triage [Candidiasis of skin and nail B37.2] and objective Complete Blood Count in Candidiasis of skin and nail (B37.2: (WBC & Differential)) targets (WBC 4.0 – 10.0 x10^3/uL (B37.2)) to prevent progression and functional morbidity.
Pathophysiology, Underlying Causes & Clinical Presentation
Pathophysiologically, Candidiasis of skin and nail (ICD-10 B37.2) is driven by cytokine pyrogen release [Candidiasis of skin and nail B37.2]; specialists in Bacterial, Viral & Fungal Infections monitor C-Reactive Protein / in Candidiasis of skin and nail (B37.2: Procalcitonin) to gauge tissue recovery.
Common Symptoms & Clinical Signs
- • Presentation of Candidiasis of skin and nail (B37.2): painful vesicular rash in Candidiasis of skin and nail (B37.2: in a dermatomal)
- • Secondary Candidiasis of skin and nail clinical sign: regional lymph node in Candidiasis of skin and nail (B37.2: tenderness or acute)
- • Symptom flares in Candidiasis of skin and nail correlating with Complete Blood Count in Candidiasis of skin and nail (B37.2: (WBC & Differential)) deviation outside WBC 4.0 – 10.0 x10^3/uL (B37.2)
- • Functional infections & antivirals impact requiring sepsis/severity red-flag triage [Candidiasis of skin and nail B37.2] evaluation (B37.2)
Candidiasis of skin and nail Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | B37.2 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Bacterial, Viral & Fungal Infections | NLM Clinical Tables |
| Diagnostic / Lab Marker: Complete Blood Count in Candidiasis of skin and nail (B37.2: (WBC & Differential)) | WBC 4.0 – 10.0 x10^3/uL (B37.2) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: C-Reactive Protein / in Candidiasis of skin and nail (B37.2: Procalcitonin) | Resolution to baseline (B37.2) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Targeted PCR / in Candidiasis of skin and nail (B37.2: Culture & Sensitivity) | Pathogen clearance / negative test (B37.2) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Candidiasis of skin and nail
Treatment selection for Candidiasis of skin and nail depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Candidiasis of skin and nail)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on High-Dose Quadrivalent Influenza Vaccine for Prevention of heart and blood vessel: What a 16,549-Participant Study Found Despite insufficient statistical power due to the impact of COVID-19, rVE point estimates demonstrated a trend toward a benefit of QIV-HD over QIV-SD. Influenza and other respiratory viruses • 2024-04-15 • Phase III Randomized Trial | N = 16,549 | 96/100 | PMID 38569647 ↗ |
| New Insights on Immunogenicity and safety of SARS-CoV-2 recombinant protein vaccine (CHO cell): What a 1,200-Participant Study Found LYB001 is highly immunogenic and retains a well-characterized safety profile in adults aged ≥ 18 years. Expert review of vaccines • 2025-12-15 • Phase III Randomized Trial | N = 1,200 | 90/100 | PMID 39720838 ↗ |
| New Insights on Benefits and safety of miconazole muco-adhesive tablet versus itraconazole in: What a 210-Participant Study Found A total of 210 patients experienced AEs during treatment with 47.7% in the experimental group and 49.8% in the control group with no deaths. Medical mycology • 2022-11-03 • Phase III Randomized Trial | N = 210 | 88/100 | PMID 36149321 ↗ |
| Can This Approach Help? Inside the Latest Research on Benefits and safety of Oteseconazole in Recurrent Vulvovaginal CONCLUSIONS: Oral oteseconazole was effective in preventing acute VVC recurrence and treating RVVC through week 48 in the CL-011 and CL-012 trials, with mostly mild TEAEs. NEJM evidence • 2022-08-15 • Phase III Randomized Trial | N = 22 | 88/100 | PMID 38319878 ↗ |
| Can This Approach Help? Inside the Latest Research on Benefits and safety of oral ibrexafungerp for the treatment of acute vulvovaginal Ibrexafungerp demonstrated statistical superiority over placebo for the primary and secondary endpoints. BJOG : an international journal of obstetrics and gynaecology • 2022-02-15 • Phase III Randomized Trial | N = 19 | 88/100 | PMID 34676663 ↗ |
Candidiasis of skin and nail Patient Community & “People Like Me” Threads
Filter Candidiasis of skin and nail community threads and patient logs by age, biological sex, dosage, and treatment duration.